BioSpace News Archive

Nemaura Medical, Inc. announces that it has entered into a preliminary agreement with EVERSANA®, a pioneer of next-generation commercial services to the global life sciences industry.

atai Life Sciences N.V. announced today its Phase 1 study has received regulatory and ethics approvals required from Medsafe and HDEC, respectively, to initiate participant enrollment.

TransCode Therapeutics, Inc. today announced that it will be presenting at the Chardan 6th Annual Genetic Medicines Conference.

Sosei Group Corporation will hold an R&D Day on Thursday, 13 October 2022, at 3:30 pm JST. The meeting will be held in person in Tokyo for institutional investors, securities analysts and the press and will also be available via a live webcast.

AVROBIO, Inc. today announced that it will present new preclinical data on novel assays used to evaluate lentiviral vector safety at the 29th Annual Congress of the European Society of Gene & Cell Therapy (ESGCT), Oct. 11-14, 2022 in Edinburgh, Scotland.

Scribe Therapeutics Inc. today announced a strategic collaboration with Sanofi for the use of Scribe’s CRISPR genome editing technologies to enable genetic modification of novel natural killer (NK) cell therapies for cancer.

Biomind Labs and Queen’s University of Belfast Receive Controlled Substances License to Commence the Production of a Novel Transdermal Drug Delivery System.

Context Therapeutics Inc. today announced updated cash guidance to extend its runway into Q1 2024.

Aktana and Envision Pharma Group announce a strategic partnership that provides medical teams with a comprehensive toolkit for more impactful scientific exchange.

Tiba Biotech , a preclinical biopharmaceutical company, today announced it has entered into a five-year, multi-million US dollar agreement with the Australian state government of New South Wales (NSW) to develop next-generation mRNA vaccines against emergency animal diseases that threaten Australia’s livestock industry and domestic food security.